In a patient with acute cardioembolic stroke likely involving the right middle cerebral artery who is receiving enoxaparin and dual antiplatelet therapy (DAPT), which antithrombotic should be stopped?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Stop DAPT and Enoxaparin Immediately in Acute Cardioembolic Stroke

In a patient with acute cardioembolic stroke involving the right MCA who is on enoxaparin and DAPT, you must stop ALL antithrombotic therapy immediately—discontinue both the enoxaparin and both antiplatelet agents. The patient will need anticoagulation for the cardioembolic source, but this should be delayed to avoid hemorrhagic transformation.

Rationale and Management Algorithm

Immediate Actions (Day 0)

  • Stop enoxaparin immediately - no role for therapeutic anticoagulation in acute stroke phase
  • Stop both antiplatelet agents (aspirin and P2Y12 inhibitor) - DAPT dramatically increases hemorrhagic transformation risk in acute stroke
  • Hold all antithrombotic therapy during the acute phase

Critical Timing Considerations

The 2020 ACC Expert Consensus provides clear guidance for patients with cerebrovascular events requiring anticoagulation 1:

For acute stroke patients who need anticoagulation (cardioembolic source), anticoagulation should be initiated between 2-14 days after the acute event, when considered safe from hemorrhagic transformation perspective 1. The exact timing within this window depends on:

  • Stroke size: Larger infarcts require longer delays (closer to 14 days)
  • Imaging findings: Presence of hemorrhagic transformation on follow-up imaging mandates further delay
  • Clinical stability: Neurological worsening suggests waiting longer

Why Stop Everything?

  1. Hemorrhagic transformation risk: Acute ischemic strokes, especially cardioembolic ones involving large vessels like the MCA, have high risk of hemorrhagic transformation. This risk is dramatically amplified by any antithrombotic therapy 1, 2.

  2. DAPT has no role in cardioembolic stroke: The patient's stroke mechanism is cardioembolic, not atherothrombotic. DAPT is indicated for atherothrombotic/noncardioembolic strokes, not cardioembolic ones 2, 3.

  3. Enoxaparin must be stopped: While the patient will ultimately need anticoagulation for their cardioembolic source, therapeutic anticoagulation in the acute stroke period increases hemorrhagic complications without proven benefit 4.

Subsequent Management (After 2-14 Days)

Once the hemorrhagic transformation risk window has passed:

  • Start oral anticoagulation alone (DOAC preferred over warfarin) 1
  • Do NOT restart antiplatelet therapy - for cardioembolic stroke with anticoagulation indication, antiplatelet therapy should be stopped entirely 1, 2
  • The guideline explicitly states: "stopping all APT and treating with an AC alone (DOAC preferred)" 1

Common Pitfalls to Avoid

Do not continue "just aspirin" - even single antiplatelet therapy increases bleeding risk when combined with anticoagulation without providing additional stroke prevention benefit in cardioembolic stroke 1.

Do not restart anticoagulation too early - the 2-14 day window exists because early anticoagulation in acute stroke increases symptomatic hemorrhagic transformation. Patience is critical 1.

Do not assume DAPT was appropriate - if this patient was on DAPT for a recent coronary intervention, that indication becomes secondary to the acute stroke. The stroke takes management priority, and the cardioembolic mechanism means anticoagulation alone (not antiplatelets) is the appropriate long-term therapy 1.

Special Consideration

If this patient had recent PCI with stent placement (reason for DAPT), this creates a complex scenario. However, the acute cardioembolic stroke still mandates stopping all antithrombotics immediately. After the 2-14 day window, if the patient is within 12 months of ACS/stenting, consider anticoagulation plus single antiplatelet (clopidogrel preferred, not aspirin) only if thrombotic risk is deemed extremely high and bleeding risk acceptable 1. Most patients should receive anticoagulation alone.

Related Questions

When can a patient who has recently suffered an acute stroke be cleared for a tooth extraction, taking into account stroke type (ischemic vs hemorrhagic), neurological stability, blood pressure control, and management of anticoagulant or antiplatelet therapy?
Should antiplatelet and anticoagulant therapy be used for long‑term secondary prevention after a cardioembolic stroke?
Can tissue plasminogen activator (tPA, alteplase) be administered to patients currently taking clopidogrel (Plavix) and apixaban (Eliquis)?
In a patient with acute ischemic stroke and supraventricular tachycardia (SVT), what antiplatelet and anticoagulant therapy is recommended?
For a patient with cardiac amyloidosis who suffered an acute ischemic stroke, should secondary prevention use a direct oral anticoagulant (DOAC) or dual antiplatelet therapy?
How many sprays of a 2.275 mg/mL topical finasteride solution should be used daily to achieve approximately a 0.5 mg dose for scalp DHT suppression?
What are the clinical indications for a 5 mg folic acid tablet?
What airway equipment sizes are recommended for a pediatric patient approximately 2 years old weighing 12 kg?
Do patients with sickle‑cell disease or sickle‑cell trait and β‑thalassemia disease or β‑thalassemia trait require folic acid supplementation, and what dose is recommended?
Can L-asparaginase be omitted in the treatment of Philadelphia-positive acute lymphoblastic leukemia?
How many milliliters of air should be used to inflate the cuff of a size 3.5 mm endotracheal tube?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.